Bleb Vascularity, Conjunctival Scarring
Conditions
Keywords
bleb, vascular change, bevacizumab, trabeculectomy, Bleb vascularity associated with increased scarring activity, Conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery, the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva.
Brief summary
The occurrence of conjunctival scarring finally leads to the obstruction of the fistula tract created by the filtering surgery. Vascular endothelial growth factor is thought to be a key role in the formation of conjunctival scar, which play a pivotal role in the wound-healing process. So it seems that the recombinant human anti-VEGF antibody could inhibit angiogenesis, and reduce the conjunctival vascular formation in the wound-healing process after glaucoma filtering surgery.
Interventions
DRUGbevacizumab
0.05ml, 1.25mg
Sponsors
Capital Medical University
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Glaucoma patients after trabeculectomy whose bleb is hyperaemia
Exclusion criteria
* Affected eye has normal IOP * Not allergic with Avastin
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| bleb vascular change | one day, one week, one month |
Countries
China
Outcome results
None listed